UBS analyst Matthew Weston downgraded Novartis (SIX:NOVN) shares from Buy to Neutral and reduced the price target from CHF111.00 to CHF104.00. The adjustment reflects a reassessment of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback